C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 1/21 (2006.01) A61K 39/095 (2006.01) C12N 15/63 (2006.01)
Patent
CA 2761924
The invention particularly relates to multivalent vaccine compositions capable of treating or preventing at least 60% and preferably 75% of the infections caused by Neisseria meningitidis, in particular those of serogroup B. To this end, the invention substantially relates to lipooligosaccharide (LOS) of N. meningitidis particularly consisting of a lipid A, an inner core, and an L6 a chain, wherein the heptose II residue of the inner core has, at the O-3 position and at the O-6 or O-7 position, a phosphoethanolamine (PEA) substituent, as well as the structure of the N. meningitidis strain capable of expressing such LOS. The invention also relates to a strain of N. meningitidis of serogroup A that comprises lipooligosaccharide (LOS) particularly consisting of a lipid A, an inner core, and an L6 a chain, wherein the heptose II residue of the inner core has, at the O-3 position, a phosphoethanolamine (PEA) substituent and does not have any PEA substituent at the O-6 and O-7 positions. The abovementioned LOS or those from the mentioned strains can be used as vaccine antigens, in particular in multivalent, inter alia, bivalent, compositions in order to provide protection against major epidemiological complexes of N. meningitides, in particular of serogroup B.
L'invention a notamment pour objet des compositions vaccinales multivalentes susceptibles de traiter ou de prévenir au moins 60 %, de préférence 75 % des infections dues à Neisseria meningitidis notamment de sérogroupe B. A cette fin, l'invention fournit en particulier un lipooligosaccharide (LOS) de N. meningitidis constitué notamment d'un lipide A, d'un core interne, d'une chaîne a de type L6, dans lequel le résidu heptose II du core interne porte en position O-3 et en position O-6 ou O-7 un substituant phosphoéthanolamine (PEA) ainsi que la construction de la souche de N. meningitidis capable d'exprimer un tel LOS. L'invention porte également sur une souche de N. meningitidis de sérogroupe A qui possède un lipooligosaccharide (LOS) constitué notamment d'un lipide A, d'un core interne, d'une chaîne a de type L6, dans lequel le résidu heptose II du core interne porte en position O-3 un substituant phosphoéthanolamine (PEA) et ne porte pas de substituant PEA en positions O-6 et O-7. Les LOS cités ou provenant des souches mentionnées peuvent être utilisés comme antigènes vaccinaux, notamment dans des compositions multivalentes, i.a. bivalentes, afin d'offrir une protection à Pencontre des complexes épidémiologiques majeurs de N. meningitidis, notamment de sérogroupe B.
Mistretta Noelle
Moreau Monique
Renauld-Mongenie Genevieve
Rokbi Bachra
Robic
Sanofi Pasteur
LandOfFree
Menigococcus vaccine containing lipooligosaccharide (los)... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Menigococcus vaccine containing lipooligosaccharide (los)..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Menigococcus vaccine containing lipooligosaccharide (los)... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1936113